Skip to main content
TipRanks
Go Ultimate75% OFF

Oncopeptides AB (ONCO) Drug Pipeline

11 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Opd5Multiple Myeloma, Relapse Multiple MyelomaPhase IWithdrawnA Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple MyelomaMay 27, 2021―
Dexamethasone, Daratumumab, MelflufenRelapsed Multiple Myeloma, Relapsed-Refractory Multiple MyelomaPhase IIITerminatedStudy of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple MyelomaNov 24, 2020―
Dexamethasone, MelphalanRrmmPhase IITerminatedA PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM PatientsMay 18, 2020―
Dexamethasone, Melphalan-Flufenamide (Melflufen)Al AmyloidosisPhase ITerminatedA Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) AmyloidosisAug 29, 2019―
Dexamethasone, MelflufenMultiple Myeloma, Renal ImpairmentPhase IITerminatedPK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal FunctionAug 14, 2018―
Dexamethasone, Daratumumab, Bortezomib, Melphalan Flufenamide (Melflufen)Multiple Myelomaphase1AndPhase2TerminatedStudy of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMMMar 06, 2018―
Dexamethasone, Pomalidomide, MelflufenMultiple MyelomaPhase IIITerminatedA Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to LenalidomideMay 09, 2017―
Dexamethasone, Melphalan Flufenamide (Melflufen)Multiple MyelomaPhase IICompletedA Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaOct 18, 2016―
Dexamethasone, MelflufenRelapsed And/Or Relapsed-Refractory Multiple Myelomaphase1AndPhase2TerminatedSafety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma PatientsJul 09, 2013―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Oncopeptides AB (SE:ONCO) have in its pipeline
Oncopeptides AB SE:ONCO is currently developing the following drugs: Opd5, Dexamethasone, Daratumumab, Melflufen, Dexamethasone, Melphalan, Dexamethasone, Melphalan-Flufenamide (Melflufen), Dexamethasone, Melflufen, Dexamethasone, Daratumumab, Bortezomib, Melphalan Flufenamide (Melflufen), Dexamethasone, Pomalidomide, Melflufen, Dexamethasone, Melphalan Flufenamide (Melflufen). These drug candidates are in various stages of clinical development as the company works toward FDA approval.